Literature DB >> 33559293

Deep Learning With 3D Convolutional Neural Network for Noninvasive Prediction of Microvascular Invasion in Hepatocellular Carcinoma.

Yongxin Zhang1,2, Xiaofei Lv3, Jiliang Qiu4, Bin Zhang1, Lu Zhang1, Jin Fang1, Minmin Li1, Luyan Chen1, Fei Wang1, Shuyi Liu1, Shuixing Zhang1.   

Abstract

BACKGROUND: Microvascular invasion (MVI) is a critical prognostic factor of hepatocellular carcinoma (HCC). However, it could only be obtained by postoperative histological examination.
PURPOSE: To develop an end-to-end deep-learning models based on MRI images for preoperative prediction of MVI in HCC patients who underwent surgical resection. STUDY TYPE: Retrospective. POPULATION: Two hundred and thirty-seven patients with histologically confirmed HCC. FIELD STRENGTH: 1.5 T and 3.0 T. SEQUENCE: Axial T2 -weighted (T2 -w) with turbo spin echo sequence, T2 -Spectral Presaturation with Inversion Recovery (T2 -SPIR), and dynamic contrast-enhanced (DCE) imaging with fat suppressed enhanced T1 high-resolution isotropic volume examination. ASSESSMENT: The patients were randomly divided into training (N = 158) and validation (N = 79) sets. Data augmentation by random rotation was performed on the training set and the sample size increased to 1940 for each MR sequence. A three-dimensional convolutional neural network (3D CNN) was used to develop four deep-learning models, including three single-layer models based on single-sequence, and fusion model combining three sequences. MVI status was obtained from the postoperative pathology reports. STATISTICAL TESTS: The dice similarity coefficient (DSC) and Hausdorff distance (HD) were applied to assess the similarity and reproducibility between the manual segmentations of tumor from two radiologists. Receiver operating characteristic curve analysis was used to evaluate model performance. MVI was identified in 92 (38.8%) patients. Good reproducibility with interobserver DSCs of 0.90, 0.89, and 0.89 and HDs of 4.09, 3.67, and 3.60 was observed for PVP, T2 WI, and T2 -SPIR, respectively. The fusion model achieved an area under the curve (AUC) of 0.81, sensitivity of 69%, and specificity of 79% in the training set and 0.72, sensitivity of 55%, and specificity of 81% in the validation set. DATA
CONCLUSION: 3D CNN model may serve as a noninvasive tool to predict MVI in HCC, whereas its accuracy needs to be enhanced with larger cohort. LEVEL OF EVIDENCE: 3 TECHNICAL EFFICACY: Stage 2.
© 2021 International Society for Magnetic Resonance in Medicine.

Entities:  

Keywords:  deep learning; hepatocellular carcinoma; microvascular invasion; three-dimensional convolutional neural network

Mesh:

Year:  2021        PMID: 33559293     DOI: 10.1002/jmri.27538

Source DB:  PubMed          Journal:  J Magn Reson Imaging        ISSN: 1053-1807            Impact factor:   4.813


  10 in total

Review 1.  Artificial intelligence for the prevention and clinical management of hepatocellular carcinoma.

Authors:  Julien Calderaro; Tobias Paul Seraphin; Tom Luedde; Tracey G Simon
Journal:  J Hepatol       Date:  2022-06       Impact factor: 30.083

2.  MVI-Mind: A Novel Deep-Learning Strategy Using Computed Tomography (CT)-Based Radiomics for End-to-End High Efficiency Prediction of Microvascular Invasion in Hepatocellular Carcinoma.

Authors:  Liyang Wang; Meilong Wu; Rui Li; Xiaolei Xu; Chengzhan Zhu; Xiaobin Feng
Journal:  Cancers (Basel)       Date:  2022-06-15       Impact factor: 6.575

Review 3.  Role of three-dimensional printing and artificial intelligence in the management of hepatocellular carcinoma: Challenges and opportunities.

Authors:  Chrysanthos D Christou; Georgios Tsoulfas
Journal:  World J Gastrointest Oncol       Date:  2022-04-15

4.  Deep-learning-based analysis of preoperative MRI predicts microvascular invasion and outcome in hepatocellular carcinoma.

Authors:  Bao-Ye Sun; Pei-Yi Gu; Ruo-Yu Guan; Cheng Zhou; Jian-Wei Lu; Zhang-Fu Yang; Chao Pan; Pei-Yun Zhou; Ya-Ping Zhu; Jia-Rui Li; Zhu-Tao Wang; Shan-Shan Gao; Wei Gan; Yong Yi; Ye Luo; Shuang-Jian Qiu
Journal:  World J Surg Oncol       Date:  2022-06-08       Impact factor: 3.253

Review 5.  Deep learning in hepatocellular carcinoma: Current status and future perspectives.

Authors:  Joseph C Ahn; Touseef Ahmad Qureshi; Amit G Singal; Debiao Li; Ju-Dong Yang
Journal:  World J Hepatol       Date:  2021-12-27

Review 6.  Progress of MRI Radiomics in Hepatocellular Carcinoma.

Authors:  Xue-Qin Gong; Yun-Yun Tao; Yao-Kun Wu; Ning Liu; Xi Yu; Ran Wang; Jing Zheng; Nian Liu; Xiao-Hua Huang; Jing-Dong Li; Gang Yang; Xiao-Qin Wei; Lin Yang; Xiao-Ming Zhang
Journal:  Front Oncol       Date:  2021-09-20       Impact factor: 6.244

7.  Predicting the Initial Treatment Response to Transarterial Chemoembolization in Intermediate-Stage Hepatocellular Carcinoma by the Integration of Radiomics and Deep Learning.

Authors:  Jie Peng; Jinhua Huang; Guijia Huang; Jing Zhang
Journal:  Front Oncol       Date:  2021-10-21       Impact factor: 6.244

8.  Diagnostic Accuracy of Artificial Intelligence Based on Imaging Data for Preoperative Prediction of Microvascular Invasion in Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.

Authors:  Jian Zhang; Shenglan Huang; Yongkang Xu; Jianbing Wu
Journal:  Front Oncol       Date:  2022-02-24       Impact factor: 6.244

9.  Application of a Convolutional Neural Network for Multitask Learning to Simultaneously Predict Microvascular Invasion and Vessels that Encapsulate Tumor Clusters in Hepatocellular Carcinoma.

Authors:  Tongjia Chu; Chen Zhao; Jian Zhang; Kehang Duan; Mingyang Li; Tianqi Zhang; Shengnan Lv; Huan Liu; Feng Wei
Journal:  Ann Surg Oncol       Date:  2022-06-26       Impact factor: 4.339

10.  Deep Learning of Liver Contrast-Enhanced Ultrasound to Predict Microvascular Invasion and Prognosis in Hepatocellular Carcinoma.

Authors:  Yafang Zhang; Qingyue Wei; Yini Huang; Zhao Yao; Cuiju Yan; Xuebin Zou; Jing Han; Qing Li; Rushuang Mao; Ying Liao; Lan Cao; Min Lin; Xiaoshuang Zhou; Xiaofeng Tang; Yixin Hu; Lingling Li; Yuanyuan Wang; Jinhua Yu; Jianhua Zhou
Journal:  Front Oncol       Date:  2022-07-07       Impact factor: 5.738

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.